MagnetisMM-6

Phase 3 Clinical Trial Comparing the Safety and Effectiveness or Elranatamab combined with Daratumumab and Lenalidomide Versus Daratumumab, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients who Defer or Are Ineligible for Transplant

What's the purpose of the trial?

The purpose of the study is to evaluate whether elranatamab in combination with daratumumab and lenalidomide (EDR) can provide superior clinical benefit compared to control therapy with daratumumab, lenalidomide and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are transplant ineligible or transplant-deferred.

Trial status

Not yet accepting

Phase
Phase 3
Enrollment
1116
Last Updated
4 days ago

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Elranatamab is a B-cell Maturation Antigen (BCMA)-CD3 bispecific antibody being tested in multiple myeloma.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.